Novartis AG ADR (NVS)vsVarex Imaging Corp (VREX)
NVS
Novartis AG ADR
$148.38
-2.52%
HEALTHCARE · Cap: $289.19B
VREX
Varex Imaging Corp
$10.09
-3.54%
HEALTHCARE · Cap: $479.42M
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 6498% more annual revenue ($56.58B vs $857.50M). NVS leads profitability with a 23.9% profit margin vs -9.6%. NVS appears more attractively valued with a PEG of 4.11. VREX earns a higher WallStSmart Score of 52/100 (C-).
NVS
Hold49
out of 100
Grade: D+
VREX
Buy52
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-65.2%
Fair Value
$91.39
Current Price
$148.38
$56.99 premium
Margin of Safety
+15.6%
Fair Value
$16.12
Current Price
$10.09
$6.03 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Reasonable price relative to book value
Earnings expanding 453.4% YoY
Areas to Watch
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Revenue declined 0.7%
1.5% revenue growth
Distress zone — elevated risk
Smaller company, higher risk/reward
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bull Case : VREX
The strongest argument for VREX centers on Price/Book, EPS Growth.
Bear Case : NVS
The primary concerns for NVS are Altman Z-Score, Debt/Equity, PEG Ratio.
Bear Case : VREX
The primary concerns for VREX are Revenue Growth, Altman Z-Score, Market Cap.
Key Dynamics to Monitor
NVS profiles as a declining stock while VREX is a turnaround play — different risk/reward profiles.
VREX carries more volatility with a beta of 0.90 — expect wider price swings.
VREX is growing revenue faster at 1.5% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
VREX scores higher overall (52/100 vs 49/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Varex Imaging Corp
HEALTHCARE · MEDICAL DEVICES · USA
Varex Imaging Corporation designs and manufactures X-ray imaging components. The company is headquartered in Salt Lake City, Utah.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?